Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

99 results about "Thyroid function" patented technology

Dissociation agent and kit

PCT designated stage expiredWO2025087337A1Biological testingFluorescence/phosphorescenceProteasePathology
Disclosed in the present invention are a dissociation agent and a detection kit for thyroid function detection. The dissociation agent comprises a protease and a reducing agent, and can effectively dissociate the bound forms of T3 and T4 in serum from binding proteins to form a free state. The dissociation agent and kit of the present invention are used for fluorescent immunochromatography detection, so that signal interference can be effectively reduced, and the sensitivity and accuracy of the detection can be improved.
Owner:LEADWAY HK

Application of reagent for detecting GPR174 gene expression level in CD4 + T cell and / or B cell in preparation of product for detecting toxic diffuse goiter

The invention discloses application of a reagent for detecting GPR174 gene expression level in CD4 + T cells and / or B cells in preparation of a product for detecting toxic diffuse goiter. The invention provides a detection marker for a toxic diffuse goiter (Graves disease). The detection marker is GPR174 expressed in a CD4 + T cell or a B cell. Experiments prove that compared with healthy people, the expression of GPR174 in CD4 + T cells or B cells in the body of a Graves disease patient is remarkably up-regulated, and the expression level of GPR174 in the CD4 + T cells and the B cells is in positive correlation with the levels of Graves disease thyroid functions FT3 (free triiodothyronine), FT4 (free tetraiodothyronine) and an autoantibody TSAb (thyroid stimulating hormone receptor stimulating antibody). The expression level of the GPR174 in the CD4 + T cell and the B cell is highly related to the occurrence of the Graves disease, and the expression level of the GPR174 in the CD4 + T cell and the B cell can be used as a detection indication of the Graves disease, so that a new thought is provided for detection and treatment of the Graves disease.
Owner:SHANGHAI FIRST PEOPLES HOSPITAL

Application of Yupingfeng pharmaceutical preparation in preparation of medicine for preventing and treating hashimoto thyroiditis

The invention relates to the technical field of biological medicine, in particular to application of a Yupingfeng pharmaceutical preparation in preparation of a medicine for preventing and treating hashimoto thyroiditis. The Yupingfeng pharmaceutical preparation provided by the invention has a good prevention and treatment effect on hashimoto thyroiditis, can be used for the whole course of hashimoto thyroiditis, including hashimoto thyroiditis in a transient hyperthyroidism stage, clinical and subclinical hypothyroidism stage and the like, and can play a role in improvement from two aspects of prevention and treatment; the pharmaceutical composition is used for preventing generation of hashimoto thyroiditis and / or treating related diseases of hashimoto thyroiditis in progress.
Owner:GUANGZHOU BAIYUNSHAN CHENLIJI PHARMA FAB CO LTD

SH1 homologous cluster fully human TSH receptor blocking monoclonal antibody group as well as preparation method and application of SH1 homologous cluster fully human TSH receptor blocking monoclonal antibody group

The invention discloses a group of blocking monoclonal antibodies of an SH1 homologous cluster fully human thyrotropin receptor (TSHR) (a TSH receptor, TSHR) as well as a preparation method and application of the blocking monoclonal antibodies of the SH1 homologous cluster fully human thyrotropin receptor (TSHR). The method comprises the following steps: sorting plasma cells and memory single B cells for specifically recognizing TSHR in peripheral blood of a patient with high TSH receptor blocking antibody (TBAb) titer by using flow cytometry, cloning antibody light and heavy chains in vitro and performing recombinant expression, and performing antibody property screening verification by using hTSHR-CHO cells. The blocking monoclonal antibody specifically targeting the human TSHR is obtained. The fully human TSH receptor blocking monoclonal antibody disclosed by the invention can be specifically combined with TSHR, and can effectively block signal transduction after the TSH is combined with the receptor; the synthesis and secretion of thyroid hormone are inhibited; expression and fibrosis of effector cell orbital fibroblasts TSHR for inhibiting thyroid-related eye diseases are remarkably relieved, and wide application prospects are achieved in treatment of Graves' diseases and diseases such as thyroid eye diseases caused by hyperthyroidism.
Owner:SHANGHAI NINTH PEOPLES HOSPITAL SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

THR-β receptor agonist, preparation method therefor, and use method therefor

Disclosed in the present invention are a THR-β receptor agonist, a preparation method therefor, and a use method therefor. The present invention provides a compound represented by formula (I), and a pharmaceutically acceptable salt or stereoisomer thereof. The agonist of the present invention has better THR-β agonistic activity and selectivity and strong liver-targeting ability, and can be used in metabolic diseases (such as non-alcoholic steatohepatitis (NASH), hepatic steatosis, hyperlipidemia, and obesity), cardiovascular diseases (such as atherosclerosis), and thyroid diseases (such as hypothyroidism and thyroid cancer).
Owner:CVI PHARMACEUTICALS SHANGHAI LTD

CHK36 homologous cluster fully human TSH receptor blocking monoclonal antibody group as well as preparation method and application thereof

The invention discloses a group of blocking monoclonal antibodies of a CHK36 homologous cluster fully human TSH receptor (TSHR) as well as a preparation method and application of the blocking monoclonal antibodies. The method comprises the following steps: sorting plasma cells and memory single B cells for specifically recognizing TSHR in peripheral blood of a patient with high TSH-blocking antibody (TBAb) titer by using flow cytometry, cloning antibody light and heavy chains in vitro and performing recombinant expression, and performing antibody property screening verification by using hTSHR-CHO cells, so as to obtain the TSHR-TBAb-TSHR-TBAb. The blocking monoclonal antibody specifically targeting the human TSHR is obtained. The fully human TSH receptor blocking monoclonal antibody disclosed by the invention can be specifically combined with TSHR, and can effectively block signal transduction after the TSH is combined with the receptor; the synthesis and secretion of thyroid hormone are inhibited; according to the present invention, with the application of the compound, the expression and the fibrosis of the effector cell orbit fibroblast TSHR inhibiting the thyroid-related eye disease can be significantly reduced, and the wide application prospect is provided in the treatment of Graves' disease (Graves' disease, GD) and diseases caused by hyperthyroidism, such as thyroid eye disease (thyroid eye disease, TED), and the like.
Owner:SHANGHAI NINTH PEOPLES HOSPITAL SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

Pharmaceutical composition containing thyroxine receptor stimulant and folic acid substances

The invention provides a pharmaceutical composition. The pharmaceutical composition is composed of a thyroxine receptor beta agonist, folic acid substances and pharmaceutically acceptable auxiliary materials. The invention also relates to application of the composition in preparation of drugs for treating chronic fatty liver diseases. The pharmaceutical composition has the advantages that the pharmaceutical composition can be used for treating the fatty liver accompanied by hypothyroidism, and adverse reactions generated by independently taking a thyroid receptor beta agonist can be reduced.
Owner:SHENZHEN AUSA PHARM CO LTD +1

Traditional Chinese medicine composition for treating hyperthyroidism and preparation method thereof

The invention discloses a traditional Chinese medicine composition for treating hyperthyroidism and a preparation method thereof, and relates to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition for treating hyperthyroidism is prepared from cyclodextrin grafted modified hollow mesoporous organic silicon nanoparticles, traditional Chinese medicine ferment powder and a traditional Chinese medicine extracting solution, the cyclodextrin-grafted modified hollow mesoporous organic silicon nano-particles are used as a carrier, traditional Chinese medicine ferment powder and a traditional Chinese medicine extracting solution are loaded, the medicine concentration of a focus part is increased, traditional Chinese medicine ingredients are rapidly released through rapid response fracture of tetrasulfide bond functional groups, and the traditional Chinese medicine composition is prepared in an active targeting and fixed-point blasting mode. The bioavailability and the onset time of the medicine are improved, the leakage risk of the medicine is jointly reduced through the gating effect of cyclodextrin and responsive release of tetrasulfide bonds, synthesis of thyroid hormone is more thoroughly inhibited under the precise effect of high-concentration medicine and multi-target immunoregulation of traditional Chinese medicine, and the recurrence rate of hyperthyroidism is reduced.
Owner:NINGXIA XINLIHENG BIOTECHNOLOGY CO LTD

A delivery carrier for targeted pituitary drug delivery and its preparation method and application

The present invention discloses a delivery carrier for targeted pituitary drug delivery and its preparation method and application. The present invention designs a carrier that can target the pituitary for drug delivery, and treats patients with spinocerebellar disorders, hypothalamic hypothyroidism, congenital single thyrotropin-releasing hormone (TRH) deficiency, non-alcoholic fatty liver disease (NAFLD), etc. The present invention modifies TRH (TRH-PEG-LP) on the surface of a PEGylated lipid carrier (PEG-LP), injects the TRH-PEG-LP carrier loaded with a near-infrared fluorescent dye (DiR) into the mouse body through the tail vein for 2 hours, takes the pituitary tissue, and observes the color development of the fluorescent dye in the pituitary of the mouse under a small animal imager (Ex / Em: 748 / 780nm), and finds that the carrier modified by TRH can target pituitary tissue well. TRH modification on the surface of the PEGylated lipid carrier can play a role in targeted delivery, and TRH can bind to the TRH receptor specifically expressed on the surface of the pituitary cells, thereby realizing targeted drug delivery of the pituitary.
Owner:NANJING DRUM TOWER HOSPITAL

Application of thyroid hormone in preparation of medicine for treating GJB2 gene mutation related congenital deafness

PendingCN120168452AOrganic active ingredientsSenses disorderCochlear structureGene mutation
The invention provides application of thyroid hormone in preparation of a medicine for treating GJB2 gene mutation related congenital deafness. Experiments prove that injection of the thyroid hormone T3 or T4 can effectively treat congenital deafness and cochlea structure development disorder caused by GJB2 gene mutation, new indications of the thyroid hormone except for hypothyroidism and thyromegaly are expanded, and the application of the thyroid hormone T3 or T4 in treating the congenital deafness caused by GJB2 gene mutation has the advantages that the application of the thyroid hormone T3 or T4 in treating the congenital deafness caused by GJB2 gene mutation has good application prospects. Compared with a traditional treatment scheme, the cochlea dysplasia of the patient can be treated while the hearing of the patient is improved, and a new treatment way is provided for related congenital deafness caused by GJB2 gene mutation.
Owner:XIEHE HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI & TECH UNIV

Composition for treating hypothyroidism

The present invention discloses a composition for treating hypothyroidism. The formula includes: placenta, antler, Pseudostellaria baicalensis, Salvia miltiorrhiza, and Herba Lycopodii. The prescription of the present invention is demonstrated to have therapeutic effects on hypothyroidism from both traditional Chinese medicine and modern medicine perspectives: from the perspective of traditional Chinese medicine, the efficacy of the present invention in replenishing qi and blood, regulating yin and yang, tonifying kidney essence, filling the marrow sea, and unblocking meridians is unique in treating goiter. From the perspective of modern medicine: Panlushending Jiawei Decoction has the effects of promoting cell reproduction, differentiation, and repairing damaged cells, and is also anti-apoptotic. It also has the effects of promoting the regeneration of vascular endothelial cells, forming new blood vessels, increasing blood flow rate, increasing blood supply, and increasing the secretion and synthesis of thyroid hormones. It can also increase the level of free hormone reabsorption from the intestine and lower the concentration of antibodies.
Owner:AFFILIATED HOSPITAL OF YULIN HEALTH SCHOOL

Method and system for processing thyroid function data based on spectrum technology

The invention discloses a method and system for processing thyroid function data based on a spectrum technology, and relates to the technical field of artificial intelligence, and the method comprises the steps: collecting a face video through employing a near infrared spectrum imaging technology, determining a face core region in the face video, and obtaining a face core region; the method comprises the following steps: capturing an absorption energy spectrum characteristic value of a human body trace substance in a human face core area to specific wave band light, obtaining spectrum original data associated with thyroid function, and synchronously recording age information of an acquisition object; on the basis of the preset rule, in combination with the age information of the collection object and the substance detection index related to the thyroid function, the thyroid function state of the collection object is graded and judged to obtain the graded judgment result, and the problem that thyroid function data cannot be processed based on the spectrum technology in the prior art is solved.
Owner:吾征智能技术(北京)有限公司

Ultrasound image-based thyroid nodule assessment system

The application relates to the technical field of ultrasonic image analysis, and discloses a thyroid nodule evaluation system based on ultrasonic images. The system obtains medical record data and medical examination data of a patient through a multidimensional acquisition module, classifies and forms a data set, analyzes the thyroid function state of each patient through an intelligent evaluation module, generates a function coefficient, analyzes the picture quality of each group of ultrasonic images again, generates corresponding detection data group Jcsj, establishes a unified evaluation standard, quickly screens out key frames from a large amount of ultrasonic image data, has high multidimensional integration efficiency, sets a fixed range threshold value for the intelligent evaluation module, analyzes and generates a nodule volume and a nodule score in combination with a medical data set, and in combination with the function coefficient, the detection data group and the nodule score, evaluates the risk grade of the thyroid nodule and the picture quality of the ultrasonic image of the patient, screens out key frames of the ultrasonic image, and outputs a treatment suggestion; and the intelligent evaluation has high precision.
Owner:THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIV

Fully human TSH receptor-blocking monoclonal antibodies targeting CHK36 homolog cluster, preparation method therefor, and application thereof

Provided are a set of fully human TSH receptor (TSHR)-blocking monoclonal antibodies targeting a CHK36 homolog cluster, a preparation method therefor, and an application thereof. The method comprises the following steps: using flow cytometry to sort plasma cells and single memory B cells that specifically recognize TSHR in peripheral blood of a patient with a high titer of TSH-blocking antibodies (TBAb), performing in vitro cloning of antibody light and heavy chains and performing recombinant expression, and using hTSHR-CHO cells to perform screening and validation of antibody properties to obtain a blocking monoclonal antibody that specifically targets human TSHR. The fully human TSH receptor-blocking monoclonal antibodies specifically bind to a TSHR, and effectively block signal transduction after a TSH binds to a receptor, inhibit the synthetic secretion of thyroid hormones, and significantly reduce and inhibit TSHR expression and fibrosis in orbital fibroblasts of effector cells associated with thyroid-related ocular diseases. The fully human TSH receptor-blocking monoclonal antibodies have broad application prospects in the treatment of Graves' disease (GD) and other diseases caused by hyperthyroidism, such as thyroid eye disease (TED).
Owner:SHANGHAI NINTH PEOPLES HOSPITAL SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

Use of triiodothyronine autoantibodies as markers of thyroid dysfunction during cancer therapy

The present disclosure relates to the field of clinical detection technology, in particular, to the application of triiodothyronine autoantibody as a marker of thyroid dysfunction during cancer treatment. The present disclosure can help clinicians to judge the real thyroid function status of patients and improve the accuracy of diagnosis.
Owner:SHENZHEN NEW INDS BIOMEDICAL ENG CO LTD +1

Medicine for treating heart failure and subclinical hypothyroidism by combining traditional Chinese medicine and western medicine

The invention belongs to the technical field of traditional Chinese medicine, and discloses a medicine for treating heart failure and subclinical hypothyroidism through combination of traditional Chinese medicine and western medicine, and the in-hospital agreement prescription comprises 10 g of radix aconiti lateralis preparata, 15 g of bighead atractylodes rhizome, 10 g of honey-fried licorice root, 15 g of earthworm, 6 g of red ginseng, 30 g of astragalus membranaceus, 10 g of cassia twig, 20 g of salvia miltiorrhiza, 12 g of angelica sinensis, 15 g of fructus amomi, 15 g of radix paeoniae rubra, 10 g of almond, 15 g of pericarpium arecae, 30 g of semen plantaginis, 12 g of polyporus umbellatus, 15 g of poria cocos, 15 g of fried semen lepidii, 12 g of rhizoma alismatis and 10 g of jujube. The yang-strengthening and foundation-consolidating decoction is combined with western medicines to treat patients suffering from heart failure and subclinical hypothyroidism, the clinical signs of the patients are obviously improved, the heart function and the thyroid function are obviously improved after the patients are subjected to the traditional Chinese and western medicine combined therapy for a period of time, and compared with the patients only treated by the western medicines, the treatment effect of the traditional Chinese and western medicine combined therapy is better. At present, no adverse reaction is found temporarily, so that the medicine has no obvious toxic and side effects, is high in safety and moderate in price, and is worthy of clinical popularization and application.
Owner:MIN COUNTY HOSPITAL OF TRADITIONAL CHINESE MEDICINE

Serum metabolite composition, kit and application

The invention discloses a novel serum metabolite composition based on dried blood spot detection and elaborates application of the serum metabolite composition as a marker in preparation of a congenital hypothyroidism diagnostic reagent or kit. The serum metabolite composition comprises thyroxine, 2-piperidone and phosphorylcholine PC (14: 0 / 20: 4). The serum metabolite composition can be used for screening and diagnosing patients with the congenital hypothyroidism, and has the characteristics of low detection cost, good repeatability and relatively high sensitivity and specificity.
Owner:DALIAN INSTITUTE OF CHEMICAL PHYSICS CHINESE ACADEMY OF SCIENCES

Thyroid function measuring and counting device

ActiveCN224070477UOrgan movement/changes detectionCounters with additional facilitiesMeasuring instrumentMechanical engineering
The utility model discloses a thyroid function measuring and counting device which comprises a measuring instrument and a counter which are movably connected with each other, a lifting handle is fixedly connected to the center of the top of the measuring instrument, a display screen is arranged on the left portion of the front face of the measuring instrument, and a connecting block is arranged on the right portion of the surface of the measuring instrument. A butt joint block is fixedly connected to the upper portion of the back face of the connecting block, and a butt joint inserting groove is formed in the surface of the connecting block. According to the utility model, the butt joint block is arranged on the back surface of the counter, the butt joint block is inserted into the butt joint slot on the surface of the connecting block, and then the positioning insertion rod is inserted into the positioning hole, so that the counter is further fixed, the stability of the counter after being installed is ensured, and during the installation operation, the limiting stop block is blocked outside the storage groove, so that the counter is prevented from being damaged. And the first telescopic rod cannot move backwards, so that when people insert the counter, the connecting block cannot move backwards, and the installation work of people is further facilitated.
Owner:TIANJIN MIFUMEI TECH DEV CO LTD

Traditional chinese medicine composition, method for preparing same, and use thereof in preparing medicament for preventing and treating thyroid disease

The present application relates to the technical field of traditional Chinese medicine, and in particular, to a traditional Chinese medicine composition, a method for preparing same, and use thereof in preparing a medicament for preventing and treating a thyroid disease. The traditional Chinese medicine composition consists of Ranunculi Ternati radix, Taraxaci herba, Cyperi rhizoma, and Semiaquilegiae radix. The method comprises: mixing and crushing formulation amounts of Ranunculi Ternati radix, Taraxaci herba, Cyperi rhizoma, and Semiaquilegiae radix; or extracting formulation amounts of Ranunculi Ternati radix, Taraxaci herba, Cyperi rhizoma, and Semiaquilegiae radix. The compounding of the four traditional Chinese medicines, Ranunculi Ternati radix, Taraxaci herba, Cyperi rhizoma, and Semiaquilegiae radix, can significantly treat hypothyroidism, thyroid nodules, and the like caused by insufficient thyroid hormones. Compared with the prior art, the traditional Chinese medicine composition features clear ingredients, good safety, and better therapeutic effects, providing technical support for the treatment of thyroid diseases with traditional Chinese medicines.
Owner:GUANGDONG PHARMA UNIV +1

Method, program, and device for diagnosing thyroid dysfunction based on electrocardiography

To provide a method for diagnosing a thyroid dysfunction based on an electrocardiography.SOLUTION: The method for diagnosing a thyroid dysfunction based on an electrocardiography includes: a step S100 for acquiring an electrocardiographic data; and a step S110 for estimating a disease rate of a thyroid dysfunction on a measurement target of the electrocardiographic data based on the electrocardiographic data using a pre-learnt neural network model. The neural network model is learnt based on a correlation between the thyroid function and a change in the electrocardiographic performance.SELECTED DRAWING: Figure 3
Owner:MEDICAL AI CO LTD

Inhibition of luteinizing hormone (LH) action as treatment of perimenopausal and postmenopausal symptoms and complications

PendingUS20260183363A1DiseasePostmenopausal symptoms
The present invention is based on the realization and verification that inhibition of Luteinizing hormone (LH) and / or luteinizing hormone / choriogonadotropin receptor (LHCGR) is useful in the treatment, alleviation or prevention of different medical states related to perimenopause and menopause in women or hypogonadism in men. Thus, an aspect of the present invention relates to LH and / or LHCGR inhibitors for use in the treatment of postmenopausal osteoporosis in a female subject. Another aspect relates to LH and / or LHCGR inhibitors for use in the reduction of fat mass in a postmenopausal female subject. A further aspect relates to LH and / or LHCGR inhibitors for use in the treatment, hypergonadotropic hypogonadism in a male subject. In addition, another aspect relates to LH and / or LHCGR inhibitors for use in the treatment of symptoms of perimenopause and / or postmenopause such as hot flashes, night sweats, osteoporosis, weight gain, hypothyroidism, conversion of T4 to T3, and / or primary hyperparathyroidism.
Owner:RIGSHOSPITALET

SH23 homologous cluster fully human TSH receptor blocking monoclonal antibody group as well as preparation method and application of SH23 homologous cluster fully human TSH receptor blocking monoclonal antibody group

The invention discloses a group of blocking monoclonal antibodies of an SH23 homologous cluster fully human thyrotropin receptor (TSHR) (a TSH receptor, TSHR), a preparation method of the blocking monoclonal antibodies, and an application of the blocking monoclonal antibodies of the SH23 homologous cluster fully human thyrotropin receptor (TSHR), the SH23 homologous cluster fully human thyrotropin receptor (TSHR) and the preparation method of the blocking monoclonal antibodies. The method comprises the following steps: sorting plasma cells and memory single B cells for specifically recognizing TSHR in peripheral blood of a patient with high TSH-blocking antibody (TBAb) titer by using flow cytometry, cloning antibody light and heavy chains in vitro and performing recombinant expression, and performing antibody property screening verification by using hTSHR-CHO cells, so as to obtain the TSHR-TBAb-TSHR-TBAb. The blocking monoclonal antibody specifically targeting the human TSHR is obtained. The fully human TSH receptor blocking monoclonal antibody disclosed by the invention can be specifically combined with TSHR, and can effectively block signal transduction after the TSH is combined with the receptor; the compound disclosed by the invention has good inhibitory activity in vitro and in vivo experiments, and has a wide application prospect in the aspect of treating Graves' diseases (Graves' disease, GD) and diseases caused by hyperthyroidism, such as thyroid eye diseases (thyroid eye disease, TED) and the like.
Owner:SHANGHAI NINTH PEOPLES HOSPITAL SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

A kaempferol conjugated derivative and its use in the preparation of a medicament for treating diarrhea

Hyperthyroid diarrhea refers to hyperthyroid diarrhea, which is mostly intractable diarrhea, due to excessive thyroid hormone causing increased intestinal peristalsis excitability and diarrhea when the thyroid function is increased, which is caused by endocrine metabolic disorder leading to gastrointestinal function disorder. The present application studies and observes the treatment effect of kaempferol coupling derivative JC-1 on diarrhea of hyperthyroid model mice, and provides a new drug treatment option for diarrhea type colon dysfunction.
Owner:JINGCHU UNIV OF TECH

Preparation method and application of rT3 recombinant monoclonal antibody

The present invention relates to the field of antibody technology, and specifically to a method for preparing and applying a recombinant monoclonal antibody against rT3. The present invention utilizes phage display technology to screen and obtain the rT3 recombinant rabbit monoclonal antibody of the present invention, wherein the heavy chain variable region thereof has the amino acid sequence shown in SEQ ID NO:1; and the light chain variable region thereof has the amino acid sequence shown in SEQ ID NO:2. The monoclonal antibody has strong specificity and high detection sensitivity, and solves the problem of low rT3 content in samples and high detection difficulty. It has been identified that repeated multiple detections using the monoclonal antibody have good stability and high accuracy. The antibody is used for the detection of rT3 content in serum, and combined with other thyroid index tests and clinical manifestations, it can diagnose hyperthyroidism and hypothyroidism, and is also clinically significant in the detection of diabetes, lung infection, myocardial infarction, cirrhosis, uremia, and some cancers.
Owner:ZHENGZHOU IMMUNO BIOTECH

Oral traditional Chinese medicine prescription for treating thyroid nodule

The invention discloses an oral traditional Chinese medicine prescription for treating thyroid nodules, and relates to the field of traditional Chinese medicine medical science, the oral traditional Chinese medicine prescription is used for treating thyroid nodules and related complications, and the oral traditional Chinese medicine prescription comprises 90-100 g of a liver-soothing and depression-relieving matrix used for relieving liver depression, qi stagnation and depression emotion; the tranquilizing and allaying excitement matrix is used for treating anxiety, insomnia and dreaminess; 165-175 g of a phlegm-reducing and stasis-resolving matrix, which is used for removing turbid phlegm and dissipating caking; the anti-inflammatory guiding medicine substrate is used for diminishing inflammation and guiding medicines of the liver-soothing and depression-relieving substrate, the tranquilizing and allaying excitement substrate and the phlegm-reducing and stagnation-resolving substrate to move upwards to the thyroid gland; wherein the anti-inflammatory guide medicine matrix comprises 15g of radix isatidis, 6g of radix scutellariae, 15g of radix puerariae, 12g of radix platycodonis and 15g of fructus arctii. The prescription has the effects of regulating qi and blood, gradually improving thyroid functions, reducing thyroid nodules and improving the living quality of patients through a synergistic effect, and manifests the essence of comprehensive conditioning of traditional Chinese medicines.
Owner:西安市长安区医院

Application of traditional Chinese medicine composition in preparation of medicine for treating thyroiditis

The invention relates to an application of a traditional Chinese medicine composition in preparing a medicine for treating thyroiditis, which is characterized in that the traditional Chinese medicine composition is prepared from astragalus membranaceus, dried ginger, salted morinda officinalis, cortex dictamni, calcined oyster shell, schisandra chinensis and divaricate saposhnikovia root. The composition can obviously improve the thyroid functions of mice and rats, obviously reduce the content of inflammatory factors TNF-alpha, IL-6 and IL-12 in serum of the mice, obviously increase the level of TGF-beta in serum of the rats and reduce the level of IL-17, and has a good treatment effect on autoimmune thyroiditis induced by combination of thyroglobulin and high-iodine water.
Owner:JIANGSU KANION PHARMA CO LTD

Method for constructing TPOAb positive animal model based on adenovirus vector

The invention relates to the technical field of biomedicine, and provides an adenovirus vector-based TPOAb positive animal model construction method which comprises the following steps: (1) constructing a TPO overexpression adenovirus vector; (2) injecting the TPO overexpression adenovirus vector into the body of an experimental animal, and inducing the generation of TPOAb; and (3) determining the optimal injection dose through a gradient dose experiment, and constructing a TPOAb positive animal model. The TPOAb positive animal model has the advantages that the generation of TPOAb in an animal body is induced by utilizing the TPO overexpression adenovirus vector through a nucleic acid immune technology, and the TPOAb positive animal model which is high in stability and modeling rate and does not interfere with the thyroid function is constructed.
Owner:ANHUI MEDICAL UNIV

Use of mulberry extract in preparation of drug for alleviating and / or treating thyroid disease

Use of mulberry extract in preparing a medicament for improving and / or treating thyroid disease is provided. This use refers to the use of mulberry extract in preparing a product for treating and / or improving thyroid disease. It has been confirmed by experiments in the present disclosure that mulberry extract can regulate the secretion levels of TSH, FT3, and FT4 in SD rats with hyperthyroidism or hypothyroidism, regulate the levels of thyroid antibodies in patients with Hashimoto's thyroiditis, and has a good improving effect on thyroid tissue lesions. As a component derived from natural plants, the mulberry extract of the present disclosure has unique advantages of small toxic and side effects and mild and long-lasting effects. Therefore, the mulberry extract with greatly improved medication safety has great advantages in the treatment of thyroid diseases.
Owner:BEIJING WEHAND BIO PHARMACEUTICAL CO LTD +1